Time is short for scientists to respond to the call for comments on the National Institutes of Health (NIH) proposed guidelines for the use of human embryonic stem (ES) cell lines and their eligibility for federal funds. On May 26, the window to provide feedback will close, and the drafted rules leave the possibility that funding for almost all existing cell lines will disappear.
In a Forum article to be published online on May 14 by Cell Press in the journal Cell Stem Cell, Patrick Taylor, deputy general counsel at Children's Hospital Boston, explains some of the legal implications of the NIH's new funding rules, should they be adopted as written. Since the rules are retroactive, he explains, ongoing research is threatened.
"Research with almost all existing cell lines will not be fundable, leaving almost no federal funds for research using cells created ethically since 2001. This will mean a loss of much of the research benefit of the last eight years, even though that research was independently reviewed and determined to be ethical under federal standards," says Taylor. "It is vitally important that scientists are aware of this problem and that the situation is resolved as quickly as possible."
Ronald McKay, director of the NIH Stem Cell Unit, agrees and points out that, as proposed, the current draft guidelines may not even allow for continued research on the 21 ES cell lines approved by President Bush in 2001. "It is important to recognize that continued access to the ES cells themselves is important for medical research," says McKay. "It is common to use the economic metaphor of the 'gold standard' when discussing the value of human ES cells. But unlike gold, stem cells will not retain value if they are locked in a bank and we cannot analyze their secrets. Continued access to these cells will ensure no delay in understanding the links between human genetics and disease," he adds.
The slow pace of commenting is symptomatic of a broader tendency within the scientific community. "Despite federal encouragement and the ease of posting a comment, scientists do not seem to be participating unless the proposals directly impact their research," outlines science writer Amy Maxman in an Analysis piece to be published by Cell Press in the journal Cell on the same day. The article explains how scientists can offer their views as part of the consultation on items listed at the Federal Register, such as by providing comments on the draft human ES cell guidelines currently under consideration, to ensure that federal agencies receive a balanced perspective of public opinion.
Source: Cell Press (news : web)
Explore further: Deal considered in U.S. stem cell debate